Olaratumab
Olaratumab Basic information
- Product Name:
- Olaratumab
- Synonyms:
-
- Olaratumab
- Research Grade Olaratumab(DHD16101)
- IMC 3G3
- IMC3G3
- IMC-3G3
- Lartruvo
- LY 3012207
- LY3012207
- CAS:
- 1024603-93-7
- MW:
- 0
- Mol File:
- Mol File
Olaratumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Olaratumab Usage And Synthesis
Uses
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1].
Clinical Use
Monoclonal antibody:
Treatment of advanced soft tissue sarcoma in
combination with doxorubicin
in vivo
IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks) in SKOV3-ip1 tumor-bearing mice, compared with the control group, IMC-3G3 treatment alone had no obvious anti-tumor effect, while in HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62%[1].
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: avoid with olaratumab in combination
with doxorubicin.
Metabolism
Mainly degraded non-specifically by proteolytic enzymes.
References
[1] Koji Matsuo, et al. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75. DOI:10.1016/j.ygyno.2013.10.027
OlaratumabSupplier
- Tel
- 27-027-83314682 13554138826
- whsrtech@vip.163.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com